gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Shown to be Effective in Treating Concussive Symptoms Associated with Mild Traumatic Brain Injuries

Core Insights - electroCore, Inc. announced new data at the 2025 International Brain Injury Association World Congress, highlighting the effectiveness of gammaCore® non-invasive vagus nerve stimulation (nVNS) in treating concussive symptoms associated with mild traumatic brain injury (mTBI) [1][3] Study Findings - A study involving 102 patients with mild TBI showed that adjunctive use of gammaCore (nVNS) significantly improved 22 out of 27 measured concussive symptoms, with notable improvements in post-traumatic headache, nausea, dizziness, and depression [3] - The study indicated no significant difference in symptom improvement between patients with recent traumatic brain injuries (three months or less) and those with older injuries (three years or more), suggesting the potential benefits of neuromodulation regardless of the time since injury [3] Expert Commentary - Dr. Michael Ament emphasized the urgent need for nonpharmaceutical treatment options for mild TBI, reinforcing the role of vagus nerve stimulation in alleviating long-term effects [2][4] - Dr. Peter Staats, Chief Medical Officer of electroCore, praised Dr. Ament's research for demonstrating the clinical efficacy of gammaCore in improving concussive symptoms in a large patient cohort [4] Company Overview - electroCore, Inc. is a commercial-stage bioelectronic medicine and wellness company focused on improving health through its nVNS technology platform, aiming to commercialize medical devices for managing and treating specific medical conditions [5]